Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 80 articles:
HTML format



Single Articles


    February 2021
  1. MOURAD MS
    Donning and Doffing.
    JAMA. 2021;325:536.
    PubMed    


    December 2020
  2. PARSONS HA, Burstein HJ
    Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
    JAMA. 2020 Dec 10. pii: 2774294. doi: 10.1001/jama.2020.23371.
    PubMed    


  3. WANG X, Wang SS, Huang H, Cai L, et al
    Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Cli
    JAMA. 2020 Dec 10. pii: 2774295. doi: 10.1001/jama.2020.23370.
    PubMed     Abstract available


    November 2020
  4. SLOMSKI A
    Long-term Mortality Outcomes in Early Breast Cancer Screening Trial.
    JAMA. 2020;324:2020.
    PubMed    


    September 2020
  5. HAMPTON T
    RNA Aptamers Deliver Chemotherapy Directly to Tumors.
    JAMA. 2020;324:829.
    PubMed    


    August 2020
  6. VOELKER R
    Breast Cancer Drug Can Be Given at Home or in the Clinic.
    JAMA. 2020;324:433.
    PubMed    


    July 2020
  7. CHLEBOWSKI RT, Anderson GL, Aragaki AK, Manson JE, et al
    Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
    JAMA. 2020;324:369-380.
    PubMed     Abstract available


  8. KURIAN AW, Bernhisel R, Stefanick ML
    Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply.
    JAMA. 2020;324:397-398.
    PubMed    


  9. FOSTIRA F, Kalfakakou D, Konstantopoulou I
    Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women.
    JAMA. 2020;324:397.
    PubMed    


  10. MINAMI CA, Freedman RA
    Menopausal Hormone Therapy and Long-term Breast Cancer Risk: Further Data From the Women's Health Initiative Trials.
    JAMA. 2020;324:347-349.
    PubMed    


  11. GRAHAM D, DiNome ML, Ganz PA
    Breast Cancer Risk-Reducing Medications.
    JAMA. 2020;324:310.
    PubMed    


  12. SHIEH Y, Tice JA
    Medications for Primary Prevention of Breast Cancer.
    JAMA. 2020;324:291-292.
    PubMed    


    June 2020
  13. VOELKER R
    Triple-Negative Breast Cancer Drug Receives Approval.
    JAMA. 2020;323:2122.
    PubMed    


    March 2020
  14. RUBIN R
    White Blood Cells Might Provide Clues to Breast Cancer Risk.
    JAMA. 2020;323:1123.
    PubMed    


  15. KURIAN AW, Bernhisel R, Larson K, Caswell-Jin JL, et al
    Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    JAMA. 2020;323:995-997.
    PubMed    


    February 2020
  16. COMSTOCK CE, Gatsonis C, Newstead GM, Snyder BS, et al
    Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
    JAMA. 2020;323:746-756.
    PubMed     Abstract available


  17. TOSTESON ANA
    An Abbreviated MRI Protocol for Breast Cancer Screening in Women With Dense Breasts: Promising Results, but Further Evaluation Required Prior to Widespread Implementation.
    JAMA. 2020;323:719-721.
    PubMed    


  18. QUAGLIARELLO V
    Tiny Branches.
    JAMA. 2020;323:711-712.
    PubMed    


  19. COMSTOCK CE, Gatsonis C, Newstead GM, Snyder BS, et al
    Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.
    JAMA. 2020;323:746-756.
    PubMed     Abstract available


  20. ABBASI J
    Artificial Intelligence Improves Breast Cancer Screening in Study.
    JAMA. 2020;323:499.
    PubMed    


  21. VOELKER R
    Another Targeted Therapy for ERBB2-Positive Breast Cancer.
    JAMA. 2020;323:408.
    PubMed    


    January 2020
  22. KRIST AH, Owens DK, Mangione CM
    Recommendations Related to Genetic Testing for Breast Cancer-Reply.
    JAMA. 2020;323:188-189.
    PubMed    


  23. PINSKY PF
    Recommendations Related to Genetic Testing for Breast Cancer.
    JAMA. 2020;323:187-188.
    PubMed    


  24. DORK T, Park-Simon TW, Hillemanns P
    Recommendations Related to Genetic Testing for Breast Cancer.
    JAMA. 2020;323:188.
    PubMed    


  25. SLAVIN SD
    Doctoring and Deportation.
    JAMA. 2020;323:119-120.
    PubMed    


    December 2019
  26. FAYANJU OLM
    Hiding in Plain Sight.
    JAMA. 2019;322:2173-2174.
    PubMed    


    September 2019
  27. SLOMSKI A
    Adjuvant Therapy for HER2-Positive Breast Cancer.
    JAMA. 2019;322:1134.
    PubMed    


  28. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:857-867.
    PubMed     Abstract available


  29. NELSON HD, Fu R, Zakher B, Pappas M, et al
    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:868-886.
    PubMed     Abstract available


  30. JIN J
    Medications to Reduce Breast Cancer Risk.
    JAMA. 2019;322:900.
    PubMed    


  31. PACE LE, Keating NL
    Medications to Reduce Breast Cancer Risk: Promise and Limitations.
    JAMA. 2019;322:821-823.
    PubMed    


    August 2019
  32. IZZO MC, Bronner G, Shields CL
    Rapidly Progressive Vision Loss in a Patient With Breast Cancer.
    JAMA. 2019 Aug 22. pii: 2749078. doi: 10.1001/jama.2019.12691.
    PubMed    


  33. OWENS DK, Davidson KW, Krist AH, Barry MJ, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2019;322:652-665.
    PubMed     Abstract available


  34. NELSON HD, Pappas M, Cantor A, Haney E, et al
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2019;322:666-685.
    PubMed     Abstract available


  35. JIN J
    Should I Be Tested for BRCA Mutations?
    JAMA. 2019;322:702.
    PubMed    


    July 2019
  36. SLOMSKI A
    Preventing Cardiotoxicity Associated With Breast Cancer Therapy.
    JAMA. 2019;322:296.
    PubMed    



  37. First PI3K Inhibitor for Breast Cancer.
    JAMA. 2019;322:19.
    PubMed    


  38. CHOI JM
    An Unexpected Asset.
    JAMA. 2019;322:29.
    PubMed    


    June 2019
  39. KEATING NL, Pace LE
    New Federal Requirements to Inform Patients About Breast Density: Will They Help Patients?
    JAMA. 2019;321:2275-2276.
    PubMed    


    May 2019
  40. KERLIKOWSKE K, Miglioretti DL, Vachon CM
    Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019.
    JAMA. 2019 May 31. pii: 2735405. doi: 10.1001/jama.2019.6247.
    PubMed    


  41. CRANDALL CJ, Livingston E
    Women's Health: A New JAMA Clinical Insights Series.
    JAMA. 2019;321:1676.
    PubMed    


  42. POLITE BN, Gluck AR, Brawley OW
    Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer.
    JAMA. 2019;321:1663-1664.
    PubMed    


    April 2019
  43. RUDDY KJ, Ganz PA
    Treatment of Nonmetastatic Breast Cancer.
    JAMA. 2019 Apr 12. pii: 2731086. doi: 10.1001/jama.2019.3927.
    PubMed    


  44. VOELKER R
    Quick Uptakes: Taking the Uncertainty Out of Interpreting BRCA Variants.
    JAMA. 2019;321:1340-1341.
    PubMed    


    February 2019
  45. SLOMSKI A
    BMI Not a Good Proxy for Breast Cancer Risk.
    JAMA. 2019;321:735.
    PubMed    


    January 2019
  46. WAKS AG, Winer EP
    Breast Cancer Treatment: A Review.
    JAMA. 2019;321:288-300.
    PubMed     Abstract available


  47. WAKS AG, Winer EP
    Breast Cancer Treatment.
    JAMA. 2019;321:316.
    PubMed    


  48. DOMCHEK SM
    Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    JAMA. 2019;321:27.
    PubMed    


    December 2018
  49. SLOMSKI A
    Chemoimmunotherapy for Triple-Negative Breast Cancer.
    JAMA. 2018;320:2521.
    PubMed    


  50. HERSHMAN DL, Unger JM, Crew K
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2270-2271.
    PubMed    


  51. LIU C, Zhang H, Sun C
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2270.
    PubMed    


  52. MAO JJ, Farrar JT
    Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
    JAMA. 2018;320:2269-2270.
    PubMed    


    August 2018
  53. LEE GK, Sheckter CC
    Breast Reconstruction Following Breast Cancer Treatment-2018.
    JAMA. 2018 Aug 31. pii: 2701789. doi: 10.1001/jama.2018.12190.
    PubMed    


  54. GROSS AL, Blot WJ, Visvanathan K
    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
    JAMA. 2018;320:597-598.
    PubMed    


  55. ABBASI J
    Can Acupuncture Keep Women on Their Breast Cancer Drugs?
    JAMA. 2018 Aug 8. pii: 2696922. doi: 10.1001/jama.2018.11068.
    PubMed    


    July 2018
  56. SLOMSKI A
    Many Women With Early Breast Cancer May Not Need Chemotherapy.
    JAMA. 2018;320:332.
    PubMed    


  57. HERSHMAN DL, Unger JM, Greenlee H, Capodice JL, et al
    Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
    JAMA. 2018;320:167-176.
    PubMed     Abstract available


  58. ABBASI J
    Immunotherapy Leads to Complete Regression in Late-Stage Breast Cancer.
    JAMA. 2018;320:127.
    PubMed    


    June 2018
  59. GILL J, Obley AJ, Prasad V
    Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    JAMA. 2018;319:2377-2378.
    PubMed    


  60. PLEVRITIS SK, Berry DA, Mandelblatt JS
    Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.
    JAMA. 2018;319:2336.
    PubMed    


  61. CHEN HH
    Contributions of Screening and Treatment to Mortality From Breast Cancer.
    JAMA. 2018;319:2335-2336.
    PubMed    


    May 2018
  62. KEATING NL, Pace LE
    Breast Cancer Screening in 2018: Time for Shared Decision Making.
    JAMA. 2018;319:1814-1815.
    PubMed    


    April 2018
  63. BEJNORDI BE, Litjens G, van der Laak JA
    Machine Learning Compared With Pathologist Assessment-Reply.
    JAMA. 2018;319:1726.
    PubMed    


  64. VAN SMEDEN M, Van Calster B, Groenwold RHH
    Machine Learning Compared With Pathologist Assessment.
    JAMA. 2018;319:1725-1726.
    PubMed    


    March 2018
  65. KATZ SJ, Jagsi R, Morrow M
    Reducing Overtreatment of Cancer With Precision Medicine: Just What the Doctor Ordered.
    JAMA. 2018;319:1091-1092.
    PubMed    


    February 2018
  66. PEACHMAN RR
    Weighing the Risks and Benefits of Hormonal Contraception.
    JAMA. 2018 Feb 28. pii: 2673941. doi: 10.1001/jama.2018.0448.
    PubMed    


  67. HENNEMAN JR
    In Shadow and Light-Images of Transformation Through Breast Cancer.
    JAMA. 2018;319:532-534.
    PubMed    


    January 2018
  68. BALLMAN KV, McCall LM, Giuliano AE
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply.
    JAMA. 2018;319:306-307.
    PubMed    


  69. UNO H, Hassett MJ, Wei LJ
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer.
    JAMA. 2018;319:306.
    PubMed    


  70. PLEVRITIS SK, Munoz D, Kurian AW, Stout NK, et al
    Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
    JAMA. 2018;319:154-164.
    PubMed     Abstract available


  71. MANSON JE, Aragaki AK, Rossouw JE
    Menopausal Estrogen Therapy and Breast Cancer Mortality-Reply.
    JAMA. 2018;319:193-194.
    PubMed    


  72. HICKEY M, McNamara HC, Mishra GD
    Menopausal Estrogen Therapy and Breast Cancer Mortality.
    JAMA. 2018;319:193.
    PubMed    


    December 2017
  73. EHTESHAMI BEJNORDI B, Veta M, Johannes van Diest P, van Ginneken B, et al
    Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer.
    JAMA. 2017;318:2199-2210.
    PubMed     Abstract available


  74. GOLDEN JA
    Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer: Helping Artificial Intelligence Be Seen.
    JAMA. 2017;318:2184-2186.
    PubMed    


    November 2017
  75. ENGELHARDT KE, Barnard C, Bilimoria KY
    Wrong-Site Surgery.
    JAMA. 2017;318:2033-2034.
    PubMed    


  76. THOMAS R, Fysh ETH, Smith NA, Lee P, et al
    Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
    JAMA. 2017;318:1903-1912.
    PubMed     Abstract available


    September 2017
  77. SLOMSKI A
    Low-Fat Diet Reduces Mortality After Breast Cancer.
    JAMA. 2017;318:1099.
    PubMed    


  78. GIULIANO AE, Ballman KV, McCall L, Beitsch PD, et al
    Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    JAMA. 2017;318:918-926.
    PubMed     Abstract available


  79. LIVINGSTON EH, Li HC
    Breast Cancer Surgery: Less Is More.
    JAMA. 2017;318:909-911.
    PubMed    


  80. MCNEIL M
    Menopausal Hormone Therapy: Understanding Long-term Risks and Benefits.
    JAMA. 2017;318:911-913.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: